Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | NPC1 | O15118 | 3/20 | 1.00 |
| ▸ | RAB9A | P51151 | 3/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | PDE4A | P27815 | 2/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 2/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 2/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 2/20 | 1.00 |
| ▸ | PADI1 | Q9ULC6 | 2/20 | 1.00 |
| ▸ | PADI3 | Q9ULW8 | 2/20 | 1.00 |
| ▸ | PADI4 | Q9UM07 | 2/20 | 1.00 |
| ▸ | PADI2 | Q9Y2J8 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | TGM2 | P21980 | 1/20 | 1.00 |
| ▸ | GALK1 | P51570 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Streptonigrin SCHEMBL29821157 | 1.00 | MAPT (1.00) | MAPTLMNASMN1; SMN2NPC1RAB9A | |
| Streptonigrin SCHEMBL3940 | 1.00 | MAPT (1.00) | MAPTLMNASMN1; SMN2NPC1RAB9A | |
| Streptonigrin SCHEMBL29374011 | 1.00 | MAPT (1.00) | MAPTLMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL25015126 | 0.93 | MAPT (0.87) | MAPTLMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL30260509 | 0.93 | MAPT (0.87) | MAPTLMNASMN1; SMN2NPC1RAB9A | |
| Streptonigrin SCHEMBL23421492 | 0.92 | LMNA (0.85) | MAPTLMNASMN1; SMN2NPC1RAB9A | |
| Streptonigrin SCHEMBL6299739 | 0.91 | LMNA (0.84) | MAPTLMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL23484220 | 0.89 | FNTA (0.82) | MAPTLMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL20257205 | 0.85 | SMN1; SMN2 (0.75) | MAPTLMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL29885591 | 0.82 | LMNA (0.70) | MAPTLMNASMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 360 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743490-A1 | HUMANIZED ANTI-CD7 ANTIBODY | Christian-Albrechts-Universität zu Kiel (DE) | 2026-05-20 | — | — | EP | claimed |
| WO-2026099502-A1 | NOVEL DRUG CONJUGATES FOR TESTING CELLULAR DRUG UPTAKE | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2026-05-15 | — | — | WO | claimed |
| EP-4676544-A1 | ANTIBODY-DRUG CONJUGATE COMPRISING ANTIBODIES AGAINST HUMAN L1CAM AND USES THEREOF | LigaChem Biosciences Inc. (KR) | 2026-01-14 | — | — | EP | claimed |
| EP-3277381-B1 | NITROBENZYL DERIVATIVES OF ANTI-CANCER AGENTS | OBI PHARMA INC (TW) | 2026-01-07 | — | — | EP | claimed |
| EP-4642492-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| US-20250242043-A1 | ANTIBODY-DRUG CONJUGATE COMPRISING ANTIBODY AGAINST HUMAN TROP2 AND USE THEREOF | LIGACHEM BIOSCIENCES, INC. (KR) | 2025-07-31 | — | — | US | claimed |
| EP-4504272-A1 | ANTIBODY-DRUG CONJUGATE COMPRISING ANTIBODY AGAINST HUMAN TROP2 AND USE THEREOF | LigaChem Biosciences Inc. (KR) | 2025-02-12 | — | — | EP | claimed |
| WO-2025012080-A1 | HUMANIZED ANTI-CD7 ANTIBODY | CHRISTIAN-ALBRECHTS-UNIVERSITÄT ZU KIEL (DE) | 2025-01-16 | — | — | WO | claimed |
| US-12168060-B2 | Antibody-drug conjugates comprising anti-B7-H3 antibodies | INTOCELL, INC. (KR) | 2024-12-17 | — | — | US | claimed |
| WO-2024240173-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2024-11-28 | — | — | WO | claimed |
| US-11413353-B2 | Conjugates comprising self-immolative groups and methods related thereto | LEGOCHEM BIOSCIENCES, INC. (KR) | 2022-08-16 | — | — | US | claimed |
| US-20220226496-A1 | LIGAND-DRUG CONJUGATE INCLUDING LINKER HAVING TRIS STRUCTURE | LEGOCHEM BIOSCIENCES, INC. (KR) | 2022-07-21 | — | — | US | claimed |
| US-20220218840-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING BRANCHED LINKERS AND METHODS RELATED THERETO | LIGACHEM BIOSCIENCES INC. (KR) | 2022-07-14 | — | — | US | claimed |
| EP-4025257-A1 | ANTIBODY-DRUG CONJUGATE COMPRISING ANTIBODY AGAINST HUMAN ROR1, AND USE FOR THE SAME | LegoChem Biosciences, Inc. (KR) | 2022-07-13 | — | — | EP | claimed |
| US-20220202950-A1 | COMPOSITIONS COMPRISING BACTERIALLY DERIVED INTACT MINICELLS FOR THERANOSTIC APPLICATIONS | ENGENEIC MOLECULAR DELIVERY PTY LTD (AU) | 2022-06-30 | — | — | US | claimed |
| WO-2022078524-A2 | SPECIFIC CONJUGATION OF AN ANTIBODY | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2022-04-21 | — | — | WO | claimed |
| EP-3218007-B1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCER | INST NAT SANTE RECH MED (FR) | 2022-04-06 | — | — | EP | claimed |
| EP-3964236-A1 | LIGAND-DRUG CONJUGATE INCLUDING LINKER HAVING TRIS STRUCTURE | LegoChem Biosciences, Inc. (KR) | 2022-03-09 | — | — | EP | claimed |
| US-20220047717-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING ANTI-B7-H3 ANTIBODIES | Y-Biologics Inc. (KR) | 2022-02-17 | — | — | US | claimed |
| EP-3316878-B1 | METHODS AND COMPOUNDS FOR THE ALLEVIATION OF PAIN | CATRINA ANCA (SE) | 2022-02-09 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220047717-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING ANTI-B7-H3 ANTIBODIES | CD274, CD44, H1-3 | MAPT 1100/4885LMNA 3972/4885SMN1; SMN2 3166/4885 |
| US-20220226496-A1 | LIGAND-DRUG CONJUGATE INCLUDING LINKER HAVING TRIS STRUCTURE | TNFSF10, TNFRSF9, ANTXR2 | MAPT 412/4885LMNA 1824/4885SMN1; SMN2 2841/4885 |
| US-20250242043-A1 | ANTIBODY-DRUG CONJUGATE COMPRISING ANTIBODY AGAINST HUMAN TROP2 AND USE THEREOF | CAMK2D, CD2BP2, CD22 | MAPT 892/4885LMNA 4694/4885SMN1; SMN2 2218/4885 |
| US-12168060-B2 | Antibody-drug conjugates comprising anti-B7-H3 antibodies | CD274, CD44, H1-3 | MAPT 1100/4885LMNA 3972/4885SMN1; SMN2 3166/4885 |
| US-20220218840-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING BRANCHED LINKERS AND METHODS RELATED THERETO | PA2G4, FCGRT, CLTB | MAPT 870/4885LMNA 4443/4885SMN1; SMN2 4519/4885 |
| US-11413353-B2 | Conjugates comprising self-immolative groups and methods related thereto | LPO, NOXO1, DAO | MAPT 933/4885LMNA 4316/4885SMN1; SMN2 3541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.